vs
MESA LABORATORIES INC（MLAB）与Riley Exploration Permian, Inc.（REPX）财务数据对比。点击上方公司名可切换其他公司
Riley Exploration Permian, Inc.的季度营收约是MESA LABORATORIES INC的1.5倍（$97.3M vs $65.1M），MESA LABORATORIES INC同比增速更快（3.6% vs -5.3%），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -1.2%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Riley Exploration Permian, Inc.是一家独立能源企业，专注于美国得克萨斯州与新墨西哥州境内的二叠纪盆地，开展原油、天然气及天然气凝析液的勘探、开发与生产业务，主打低成本陆上储备开发，为北美市场供应稳定能源产品。
MLAB vs REPX — 直观对比
营收规模更大
REPX
是对方的1.5倍
$65.1M
营收增速更快
MLAB
高出8.9%
-5.3%
两年增速更快
MLAB
近两年复合增速
-1.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $97.3M |
| 净利润 | $3.6M | — |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | 26.9% |
| 净利率 | 5.6% | — |
| 营收同比 | 3.6% | -5.3% |
| 净利润同比 | 316.6% | — |
| 每股收益（稀释后） | $0.65 | $4.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABREPX
| Q4 25 | $65.1M | $97.3M | ||
| Q3 25 | $60.7M | $106.9M | ||
| Q2 25 | $59.5M | $85.4M | ||
| Q1 25 | $62.1M | $102.5M | ||
| Q4 24 | $62.8M | $102.7M | ||
| Q3 24 | $57.8M | $102.3M | ||
| Q2 24 | $58.2M | $105.4M | ||
| Q1 24 | $58.9M | $99.7M |
净利润MLABREPX
| Q4 25 | $3.6M | — | ||
| Q3 25 | $2.5M | $16.3M | ||
| Q2 25 | $4.7M | $30.5M | ||
| Q1 25 | $-7.1M | $28.6M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $3.4M | $25.7M | ||
| Q2 24 | $3.4M | $33.5M | ||
| Q1 24 | $-254.6M | $18.8M |
毛利率MLABREPX
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABREPX
| Q4 25 | 12.2% | 26.9% | ||
| Q3 25 | 7.8% | 27.0% | ||
| Q2 25 | 5.1% | 33.7% | ||
| Q1 25 | 2.4% | 48.3% | ||
| Q4 24 | 9.2% | 31.2% | ||
| Q3 24 | 6.1% | 17.1% | ||
| Q2 24 | 9.6% | 50.9% | ||
| Q1 24 | -460.6% | 50.7% |
净利率MLABREPX
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.1% | 15.3% | ||
| Q2 25 | 8.0% | 35.7% | ||
| Q1 25 | -11.4% | 27.9% | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | 5.9% | 25.1% | ||
| Q2 24 | 5.8% | 31.8% | ||
| Q1 24 | -432.2% | 18.8% |
每股收益（稀释后）MLABREPX
| Q4 25 | $0.65 | $4.02 | ||
| Q3 25 | $0.45 | $0.77 | ||
| Q2 25 | $0.85 | $1.44 | ||
| Q1 25 | $-1.30 | $1.36 | ||
| Q4 24 | $-0.31 | $0.52 | ||
| Q3 24 | $0.63 | $1.21 | ||
| Q2 24 | $0.62 | $1.59 | ||
| Q1 24 | $-47.26 | $0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | — |
| 总债务越低越好 | $68.4M | $247.9M |
| 股东权益账面价值 | $186.7M | $634.2M |
| 总资产 | $434.8M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.39× |
8季度趋势，按日历期对齐
现金及短期投资MLABREPX
| Q4 25 | $29.0M | — | ||
| Q3 25 | $20.4M | — | ||
| Q2 25 | $21.3M | — | ||
| Q1 25 | $27.3M | — | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $24.3M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $28.2M | — |
总债务MLABREPX
| Q4 25 | $68.4M | $247.9M | ||
| Q3 25 | $69.4M | $367.0M | ||
| Q2 25 | $70.3M | $275.2M | ||
| Q1 25 | $71.3M | $249.3M | ||
| Q4 24 | $72.2M | $269.5M | ||
| Q3 24 | $73.1M | $288.6M | ||
| Q2 24 | $74.1M | $322.7M | ||
| Q1 24 | — | $341.8M |
股东权益MLABREPX
| Q4 25 | $186.7M | $634.2M | ||
| Q3 25 | $178.5M | $566.5M | ||
| Q2 25 | $172.5M | $556.9M | ||
| Q1 25 | $159.8M | $532.4M | ||
| Q4 24 | $155.2M | $510.6M | ||
| Q3 24 | $161.5M | $507.4M | ||
| Q2 24 | $150.7M | $489.0M | ||
| Q1 24 | $145.4M | $434.6M |
总资产MLABREPX
| Q4 25 | $434.8M | $1.2B | ||
| Q3 25 | $430.4M | $1.2B | ||
| Q2 25 | $435.7M | $1.0B | ||
| Q1 25 | $433.3M | $994.9M | ||
| Q4 24 | $433.3M | $993.5M | ||
| Q3 24 | $454.1M | $997.9M | ||
| Q2 24 | $440.4M | $1.0B | ||
| Q1 24 | $446.8M | $956.4M |
负债/权益比MLABREPX
| Q4 25 | 0.37× | 0.39× | ||
| Q3 25 | 0.39× | 0.65× | ||
| Q2 25 | 0.41× | 0.49× | ||
| Q1 25 | 0.45× | 0.47× | ||
| Q4 24 | 0.47× | 0.53× | ||
| Q3 24 | 0.45× | 0.57× | ||
| Q2 24 | 0.49× | 0.66× | ||
| Q1 24 | — | 0.79× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $64.9M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 27.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABREPX
| Q4 25 | $18.8M | $64.9M | ||
| Q3 25 | $8.2M | $63.6M | ||
| Q2 25 | $1.9M | $33.6M | ||
| Q1 25 | $12.7M | $50.4M | ||
| Q4 24 | $18.1M | $66.4M | ||
| Q3 24 | $5.3M | $72.1M | ||
| Q2 24 | $10.7M | $51.6M | ||
| Q1 24 | $12.9M | $56.1M |
自由现金流MLABREPX
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $12.3M | — |
自由现金流率MLABREPX
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 21.0% | — |
资本支出强度MLABREPX
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 0.9% | — |
现金转化率MLABREPX
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | 3.90× | ||
| Q2 25 | 0.40× | 1.10× | ||
| Q1 25 | — | 1.76× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | 2.81× | ||
| Q2 24 | 3.17× | 1.54× | ||
| Q1 24 | — | 2.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
REPX
暂无分部数据
